{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:38:16Z","timestamp":1790800696140,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd003965.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T00:00:00Z","timestamp":1583971200000}}],"reference-count":229,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd003965.pub3","type":"journal-article","created":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T09:00:45Z","timestamp":1584003645000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Immunosuppressive agents for treating IgA nephropathy"],"prefix":"10.1002","author":[{"given":"Patrizia","family":"Natale","sequence":"first","affiliation":[{"name":"University of Bari; Department of Emergency and Organ Transplantation; Bari Italy"},{"name":"The University of Sydney; Sydney School of Public Health; Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suetonia C","family":"Palmer","sequence":"additional","affiliation":[{"name":"University of Otago Christchurch; Department of Medicine; 2 Riccarton Ave PO Box 4345 Christchurch New Zealand 8140"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marinella","family":"Ruospo","sequence":"additional","affiliation":[{"name":"University of Bari; Department of Emergency and Organ Transplantation; Bari Italy"},{"name":"The University of Sydney; Sydney School of Public Health; Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria M","family":"Saglimbene","sequence":"additional","affiliation":[{"name":"University of Bari; Department of Emergency and Organ Transplantation; Bari Italy"},{"name":"The University of Sydney; Sydney School of Public Health; Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan C","family":"Craig","sequence":"additional","affiliation":[{"name":"The Children's Hospital at Westmead; Cochrane Kidney and Transplant, Centre for Kidney Research; Westmead NSW Australia 2145"},{"name":"Flinders University; College of Medicine and Public Health; Adelaide SA Australia 5001"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariacristina","family":"Vecchio","sequence":"additional","affiliation":[{"name":"Danone Research; RD 128 Palaiseau Cedex France 91767"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua A","family":"Samuels","sequence":"additional","affiliation":[{"name":"UT-Houston Health Science Center; Division of Pediatric Nephrology and Hypertension; 6431 Fannin Street, MSB 3-121 Houston TX USA 77030"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald A","family":"Molony","sequence":"additional","affiliation":[{"name":"UT-Houston Health Science Center; Internal Medicine; Division of Renal Diseases and Hypertension 64312 Fannin St Houston TX USA 77030"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco Paolo","family":"Schena","sequence":"additional","affiliation":[{"name":"University of Bari; Department of Emergency and Organ Transplantation; Bari Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni FM","family":"Strippoli","sequence":"additional","affiliation":[{"name":"University of Bari; Department of Emergency and Organ Transplantation; Bari Italy"},{"name":"The University of Sydney; Sydney School of Public Health; Sydney Australia"},{"name":"The Children's Hospital at Westmead; Cochrane Kidney and Transplant, Centre for Kidney Research; Westmead NSW Australia 2145"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,3,12]]},"reference":[{"issue":"Abstracts","key":"10.1002\/14651858.CD003965.pub3-BIB0001|cit1","first-page":"48A","article-title":"Reduction of proteinuria observed in response to high dose ACE inhibition and omega-3 fatty acids in pts with IgA nephropathy. Report from the second North American IgA nephropathy trial [abstract no: SA-FC059]","volume":"18","author":"Hogg","year":"2007","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstracts","key":"10.1002\/14651858.CD003965.pub3-BIB0007|cit2","first-page":"567A","article-title":"Preliminary report from the second North American IgA nephropathy (IgAN) trial [abstract no: F-PO1098]","volume":"17","author":"Hogg","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD003965.pub3-BIB0002|cit3","first-page":"523A","article-title":"Dose-dependency of the effect of omega-3 fatty acids (O3FA) on proteinuria in patients with IgA nephropathy: report from the 2nd North American IgA nephropathy trial [abstract no: F-PO860]","volume":"16","author":"Hogg","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD003965.pub3-BIB0003|cit4","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1053\/j.ajkd.2015.06.013","article-title":"Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy","volume":"66","author":"Hogg","year":"2015","journal-title":"American Journal of Kidney Diseases"},{"issue":"6","key":"10.1002\/14651858.CD003965.pub3-BIB0004|cit5","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.2215\/CJN.02300606","article-title":"Efficacy of omega-3 fatty acids in children and adults with IgA nephropathy is dosage- and size-dependent","volume":"1","author":"Hogg","year":"2006","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"key":"10.1002\/14651858.CD003965.pub3-BIB0005|cit6","doi-asserted-by":"crossref","unstructured":"Hogg RJ SouthWest Pediatric Nephrology Study Group A randomized controlled trial of mycophenolate mofetil in patients with IgA nephropathy: study protocol Personal communication 2003","DOI":"10.1186\/1471-2369-5-3"},{"key":"10.1002\/14651858.CD003965.pub3-BIB0006|cit7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1471-2369-5-3","article-title":"A randomized controlled trial of mycophenolate mofetil in patients with IgA nephropathy [ISRCTN62574616]","volume":"5","author":"Hogg","year":"2004","journal-title":"BMC Nephrology"},{"issue":"8","key":"10.1002\/14651858.CD003965.pub3-BIB0008|cit8","first-page":"1684","article-title":"A controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy [abstract]","volume":"11","author":"Ballardie","year":"1996","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD003965.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1681\/ASN.V131142","article-title":"Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy","volume":"13","author":"Ballardie","year":"2002","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstracts","key":"10.1002\/14651858.CD003965.pub3-BIB0010|cit10","first-page":"4B","article-title":"Effects of blisibimod, a selective inhibitor of b-cell activating factor, in patients with IgA nephropathy [abstract no: FR-PO1128]","volume":"27","author":"Barratt","year":"2016","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD003965.pub3-BIB0011|cit11","first-page":"527A","article-title":"Leflunomide plus low dose prednisone reduced urinary VCAM-1 level in progressive IgA nephropathy [abstract no: F-PO1851]","volume":"19","author":"Cao","year":"2008","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD003965.pub3-BIB0012|cit12","first-page":"232A","article-title":"Leflunomide plus low dose prednisone reduced serum interleukin-18 level in progressive IgA nephropathy [abstract no: TH-PO515]","volume":"20","author":"Zhou","year":"2009","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstracts","key":"10.1002\/14651858.CD003965.pub3-BIB0013|cit13","first-page":"240A","article-title":"Effects of candesartan on clinical remission in IgA nephropathy treated with steroid pulse therapy and tonsilectomy (CAST IgA Study) - a randomized control study [abstract no: TH-PO661]","volume":"26","author":"Kohagura","year":"2015","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Sept","key":"10.1002\/14651858.CD003965.pub3-BIB0014|cit14","first-page":"57A","article-title":"Control study of effects of mycophenolate mofetil on IgA nephropathy [abstract no: A0311]","volume":"11","author":"Chen","year":"2000","journal-title":"Journal of the American Society of Nephrology"},{"issue":"September, Prog","key":"10.1002\/14651858.CD003965.pub3-BIB0015|cit15","first-page":"14A","article-title":"A randomized control study of mycophenolate mofetil treatment in severe IgA nephropathy [abstract no: F-FC065]","volume":"13","author":"Chen","year":"2002","journal-title":"Journal of the American Society of Nephrology"},{"issue":"12","key":"10.1002\/14651858.CD003965.pub3-BIB0016|cit16","first-page":"796","article-title":"A randomized control trial of mycophenolate mofeil treatment in severe IgA nephropathy","volume":"82","author":"Chen","year":"2002","journal-title":"Chung-Hua i Hsueh Tsa Chih [Chinese Medical Journal]"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD003965.pub3-BIB0017|cit17","first-page":"66","article-title":"72 weeks follow-up study of effects of mycophenolate mofetil on IgA nephropathy [abstract no: A0353]","volume":"12","author":"Chen","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD003965.pub3-BIB0018|cit18","first-page":"142","article-title":"A phase II study evaluating the safety and efficacy of belimumab in patients with IgA nephropathy [abstract]","volume":"4","author":"Cheung","year":"2018","journal-title":"Kidney Diseases"},{"issue":"11","key":"10.1002\/14651858.CD003965.pub3-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1093\/ndt\/gfr072","article-title":"Low-dose sirolimus combined with angiotensin-converting enzyme inhibitor and statin stabilizes renal function and reduces glomerular proliferation in poor prognosis IgA nephropathy","volume":"26","author":"Cruzado","year":"2011","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD003965.pub3-BIB0020|cit20","first-page":"555A","article-title":"Low dose of sirolimus for the treatment of poor-prognosis IgA nephropathy: a prospective controlled trial [abstract no: F-PO1964]","volume":"19","author":"Curzado","year":"2008","journal-title":"Journal of the American Society of Nephrology"},{"issue":"10","key":"10.1002\/14651858.CD003965.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1093\/ndt\/gfh974","article-title":"Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial","volume":"20","author":"Frisch","year":"2005","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Nov","key":"10.1002\/14651858.CD003965.pub3-BIB0022|cit22","first-page":"753A","article-title":"Mycophenolate mofetil vs placebo in patients at high risk for progressive IgA nephropathy: a double blind RCT [abstract no: SU-PO987]","volume":"14","author":"Frisch","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD003965.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1023\/A:1014424723466","article-title":"Efficacy of immunosuppressive therapy in IgA nephropathy presenting with isolated hematuria","volume":"33","author":"Harmankaya","year":"2002","journal-title":"International Urology & Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD003965.pub3-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"159","DOI":"10.23876\/j.krcp.2017.36.2.159","article-title":"Efficacy and safety of adding mizoribine to standard treatment in patients with immunoglobulin A nephropathy: a randomized controlled trial","volume":"36","author":"Hirai","year":"2017","journal-title":"Kidney Research & Clinical Practice"},{"issue":"4","key":"10.1002\/14651858.CD003965.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1080\/08860220701260511","article-title":"Prednisolone co-administered with losartan confers renoprotection in patients with IgA nephropathy","volume":"29","author":"Horita","year":"2007","journal-title":"Renal Failure"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD003965.pub3-BIB0026|cit26","first-page":"iv332","article-title":"Effects of co-administration of prednisolone plus losartan in moderate proteinuric IgA nephropathy [abstract no: MP099]","volume":"21","author":"Horita","year":"2006","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD003965.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1053\/j.ajkd.2016.11.027","article-title":"Mycophenolate mofetil combined with prednisone versus full-dose prednisone in IgA nephropathy with active proliferative lesions: a randomized controlled trial","volume":"69","author":"Hou","year":"2017","journal-title":"American Journal of Kidney Diseases"},{"key":"10.1002\/14651858.CD003965.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1159\/000422413","article-title":"Alternate-day prednisone therapy in IgA nephropathy. Preliminary analysis of a prospective, randomized, controlled trial","volume":"104","author":"Julian","year":"1993","journal-title":"Contributions to Nephrology"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD003965.pub3-BIB0029|cit29","first-page":"681","article-title":"Alternate-day prednisone treatment of patients with IgA nephropathy [abstract no: 99P]","volume":"4","author":"Julian","year":"1993","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD003965.pub3-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s101570300006","article-title":"A comparison of corticosteroid and warfarin therapy in IgA nephropathy with crescent formation: preliminary trial","volume":"7","author":"Kanno","year":"2003","journal-title":"Clinical & Experimental Nephrology"},{"issue":"Suppl","key":"10.1002\/14651858.CD003965.pub3-BIB0031|cit31","first-page":"A18","article-title":"A randomized prospective control study of low dose prednisolone therapy for IgA nephropathy: its usefulness and limitations [abstract]","volume":"5","author":"Katafuchi","year":"1999","journal-title":"Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD003965.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/S0272-6386(03)00194-X","article-title":"Controlled, prospective trial of steroid treatment in IgA nephropathy: a limitation of low-dose prednisolone therapy","volume":"41","author":"Katafuchi","year":"2003","journal-title":"American Journal of Kidney Diseases"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003965.pub3-BIB0033|cit33","first-page":"S355","article-title":"Low dose steroid therapy in IgA nephropathy: a randomized prospective control study [abstract no: P1126]","volume":"3","author":"Katafuchi","year":"1997","journal-title":"Nephrology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD003965.pub3-BIB0034|cit34","first-page":"108","article-title":"Pathological sub-analysis of randomized controlled trial of tonsillectomy combined with steroid pulse therapy vs steroid pulse monotherapy in IGA nephropathy [abstract no: PS1-096]","volume":"19","author":"Katafuchi","year":"2014","journal-title":"Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD003965.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/s10157-015-1159-2","article-title":"Pathological sub-analysis of a multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy versus steroid pulse monotherapy in patients with immunoglobulin A nephropathy","volume":"20","author":"Katafuchi","year":"2016","journal-title":"Clinical & Experimental Nephrology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD003965.pub3-BIB0036|cit36","first-page":"18","article-title":"A multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy in patients with IgA nephropathy [abstract no: SY8-05]","volume":"19","author":"Kawamura","year":"2014","journal-title":"Nephrology"},{"issue":"8","key":"10.1002\/14651858.CD003965.pub3-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1093\/ndt\/gfu020","article-title":"A multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy in patients with immunoglobulin A nephropathy","volume":"29","author":"Kawamura","year":"2014","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD003965.pub3-BIB0038|cit38","unstructured":"Yoshimura M Imasawa T Nakayama M Wada A Katahuti R Kawamura T Tonsillectomy and steroid pulse therapy in IgA nephropathy: a randomized, controlled trial versus a multicenter prospective controlled study [abstract no: SU329] World Congress of Nephrology; 2009 May 22-26; Milan, Italy 2009"},{"issue":"8","key":"10.1002\/14651858.CD003965.pub3-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"e71545","DOI":"10.1371\/journal.pone.0071545","article-title":"Tacrolimus decreases albuminuria in patients with IgA nephropathy and normal blood pressure: a double-blind randomized controlled trial of efficacy of tacrolimus on IgA nephropathy","volume":"8","author":"Kim","year":"2013","journal-title":"PLoS ONE [Electronic Resource]"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD003965.pub3-BIB0040|cit40","first-page":"192A","article-title":"Double-blind, randomized placebo-controlled clinical trial for the effiicacy of tacrolimus in the patients with albuminuric, normotensive IgA nephropathy [abstract no: TH-PO410]","volume":"23","author":"Kim","year":"2012","journal-title":"Journal of the American Society of Nephrology"},{"issue":"11","key":"10.1002\/14651858.CD003965.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"e0188375","DOI":"10.1371\/journal.pone.0188375","article-title":"Short-term anti-proteinuric effect of tacrolimus is not related to preservation of the glomerular filtration rate in IgA nephropathy: a 5-year follow-up study.[Erratum in: PLoS One. 2018 Jan 29;13(1):e0192266; PMID: 29377948]","volume":"12","author":"Yu","year":"2017","journal-title":"PLoS ONE [Electronic Resource]"},{"issue":"2","key":"10.1002\/14651858.CD003965.pub3-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1159\/000188848","article-title":"Steroid therapy during the early stage of progressive IgA nephropathy. A 10-year follow-up study","volume":"72","author":"Kobayashi","year":"1996","journal-title":"Nephron"},{"issue":"4","key":"10.1002\/14651858.CD003965.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1007\/s10157-008-0036-7","article-title":"Clinical assessment of low-dose steroid therapy for patients with IgA nephropathy: a prospective study in a single center","volume":"12","author":"Koike","year":"2008","journal-title":"Clinical & Experimental Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD003965.pub3-BIB0044|cit44","first-page":"C4","article-title":"Randomized, prospective, multcenter trial for treatment of IgA nephropathy in children [abstract no: S-5]","volume":"10","author":"Koitabashi","year":"1996","journal-title":"Pediatric Nephrology"},{"issue":"Abstracts","key":"10.1002\/14651858.CD003965.pub3-BIB0045|cit45","first-page":"B5","article-title":"A randomized trial of rituximab in advanced IgA nephropathy [abstract no: SA-PO1098]","volume":"26","author":"Lafayette","year":"2015","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD003965.pub3-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1681\/ASN.2016060640","article-title":"A randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction","volume":"28","author":"Lafayette","year":"2017","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD003965.pub3-BIB0047|cit47","first-page":"174","article-title":"Corticosteroid therapy in IgA nephropathy with nephrotic syndrome: a long-term controlled trial","volume":"26","author":"Lai","year":"1986","journal-title":"Clinical Nephrology"},{"key":"10.1002\/14651858.CD003965.pub3-BIB0052|cit48","unstructured":"Lai KN Lai FM Short-term controlled trial of cyclosporin A therapy in IgA nephropathy [abstract] 10th International Congress of Nephrology; 1987 Jul 26-31; London, UK 1987 73"},{"key":"10.1002\/14651858.CD003965.pub3-BIB0049|cit49","unstructured":"Lai KN Lai FM Chui SH Effect of cyclosporin A on cellular immunity in IgA nephropathy [abstract] 10th International Congress of Nephrology; 1987 Jul 26-31; London, UK 1987 388"},{"issue":"4","key":"10.1002\/14651858.CD003965.pub3-BIB0048|cit50","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1159\/000185668","article-title":"Effect of ciclosporin on lymphocyte subpopulations and immunoglobulin production in IgA nephropathy","volume":"52","author":"Lai","year":"1989","journal-title":"Nephron"},{"issue":"6607","key":"10.1002\/14651858.CD003965.pub3-BIB0050|cit51","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1136\/bmj.295.6607.1165","article-title":"Cyclosporin treatment of IgA nephropathy: a short term controlled trial","volume":"295","author":"Lai","year":"1987","journal-title":"British Medical Journal Clinical Research Ed"},{"key":"10.1002\/14651858.CD003965.pub3-BIB0051|cit52","unstructured":"Lai KN Lai FM Vallance-Owen J Short-term controlled trial of cyclosporin A in therapy in IgA nephropathy [abstract no: 12] 23rd Annual Meeting Australasian Society of Nephrology; 1987 Apr 1-3; Adelaide, SA 1987 13"},{"issue":"3","key":"10.1002\/14651858.CD003965.pub3-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/BF02550423","article-title":"Effect of cyclosporine A on circulating immune complexes in IgA nephropathy","volume":"23","author":"Lai","year":"1991","journal-title":"International Urology & Nephrology"},{"issue":"3 Suppl 4","key":"10.1002\/14651858.CD003965.pub3-BIB0054|cit54","first-page":"297","article-title":"A short-term controlled trial of cyclosporine A in IgA nephropathy","volume":"20","author":"Lai","year":"1988","journal-title":"Transplantation Proceedings"},{"issue":"1","key":"10.1002\/14651858.CD003965.pub3-BIB0055|cit55","first-page":"71","article-title":"Renoprotective effect of the combined use of steroid and angiotensin II receptor blocker in IgA Nephropathy","volume":"24","author":"Kim","year":"2005","journal-title":"Korean Journal of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD003965.pub3-BIB0056|cit56","first-page":"539","article-title":"Effect of combined treatment of steroid and angiotensin II receptor blocker (ARB) in proteinuric IgA nephropathy","volume":"22","author":"Lee","year":"2003","journal-title":"Korean Journal of Nephrology"},{"issue":"8","key":"10.1002\/14651858.CD003965.pub3-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"509","DOI":"10.5414\/CPP48509","article-title":"Comparison of the therapeutic effects of leflunomide and mycophenolate mofetil in the treatment of immunoglobulin A nephropathy manifesting with nephrotic syndrome","volume":"48","author":"Liu","year":"2010","journal-title":"International Journal of Clinical Pharmacology & Therapeutics"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD003965.pub3-BIB0058|cit58","first-page":"636A","article-title":"Medium dose of cyclosporine combined with methylprednisolone in IgA nephropathy: prospective randomized controlled trial [abstract no: SA-PO2300]","volume":"21","author":"Liu","year":"2010","journal-title":"Journal of the American Society of Nephrology"},{"issue":"7","key":"10.1002\/14651858.CD003965.pub3-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"675","DOI":"10.2169\/internalmedicine.53.1136","article-title":"Comparison of glucocorticoids alone and combined with cyclosporine A in patients with IgA nephropathy: a prospective randomized controlled trial","volume":"53","author":"Liu","year":"2014","journal-title":"Internal Medicine"},{"key":"10.1002\/14651858.CD003965.pub3-BIB0060|cit60","unstructured":"Del Vecchio L Pozzi C Andrulli S Pani A Scaini P Fogazzi G Corticosteroids and azathioprine vs corticosteroids alone in IgA nephropathy: a randomised, controlled trial [abstract no: SA770] World Congress of Nephrology; 2009 May 22-26; Milan, Italy 2009"},{"issue":"5","key":"10.1002\/14651858.CD003965.pub3-BIB0061|cit61","first-page":"308","article-title":"Combined treatment with steroids and azathioprine in IgA nephropathy: design of a prospective randomised multicentre trial","volume":"12","author":"Locatelli","year":"1999","journal-title":"Journal of Nephrology"},{"issue":"10","key":"10.1002\/14651858.CD003965.pub3-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1681\/ASN.2010010117","article-title":"Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy","volume":"21","author":"Pozzi","year":"2010","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD003965.pub3-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"86","DOI":"10.5301\/jn.5000110","article-title":"IgA nephropathy with severe chronic renal failure: a randomized controlled trial of corticosteroids and azathioprine","volume":"26","author":"Pozzi","year":"2013","journal-title":"Journal of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD003965.pub3-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1440-1797.2006.00547.x","article-title":"Randomised controlled trial of leflunomide in the treatment of immunoglobulin A nephropathy","volume":"11","author":"Lou","year":"2006","journal-title":"Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD003965.pub3-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1053\/j.ajkd.2008.07.029","article-title":"Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial","volume":"53","author":"Lv","year":"2009","journal-title":"American Journal of Kidney Diseases"},{"issue":"Abstracts","key":"10.1002\/14651858.CD003965.pub3-BIB0066|cit66","first-page":"57A","article-title":"Addition of steroids to ACE inhibitors is more preferred to patients with IgA nephropathy: a prospective randomized controlled trial [abstract no: SA-FC105]","volume":"18","author":"Lv","year":"2007","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD003965.pub3-BIB0067|cit67","first-page":"343","article-title":"A prospective placebo-controlled randomized study of mycophenolate mofetil treatment for IGA nephropathy: lack of clinical efficacy after three years [abstract no: T194]","volume":"18","author":"Maes","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD003965.pub3-BIB0068|cit68","first-page":"114A","article-title":"A prospective placebo-controlled randomized single centre study of mycophenolate mofetil treatment for IGA nephropathy: lack of clinical efficacy after two years [abstract no: A0599]","volume":"12","author":"Maes","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD003965.pub3-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1111\/j.1523-1755.2004.00588.x","article-title":"Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study","volume":"65","author":"Maes","year":"2004","journal-title":"Kidney International"},{"issue":"4","key":"10.1002\/14651858.CD003965.pub3-BIB0070|cit70","first-page":"248","article-title":"Prospective randomized controlled multicenter trial on steroids plus ramipril in proteinuric IgA nephropathy","volume":"14","author":"Manno","year":"2001","journal-title":"Journal of Nephrology"},{"key":"10.1002\/14651858.CD003965.pub3-BIB0071|cit71","unstructured":"Manno C Torres DD Pesce F Rossini M Schena FP Long-term prospective randomized controlled multicentre trial on steroids plus ramipril in proteinuric IgA nephropathy [abstract no: LB-001] American Society of Nephrology (ASN) Renal Week; 2008 Nov 4-9; Philadelphia,PA 2008"},{"issue":"12","key":"10.1002\/14651858.CD003965.pub3-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1093\/ndt\/gfp356","article-title":"Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy.[Erratum in: Nephrol Dial Transplant. 2010 Apr;25(4):1363-4]","volume":"24","author":"Manno","year":"2009","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD003965.pub3-BIB0073|cit73","unstructured":"Torres D Rossini M Manno C Gesualdo L Grandaliano G Schena FP Steroids plus ramipril versus ramipril alone in the treatment of IgA nephropathy: interim analysis of a prospective, controlled, randomized, multicenter trial [abstract no: MO27] 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal 2004 222 3"},{"issue":"6","key":"10.1002\/14651858.CD003965.pub3-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1007\/s10157-016-1226-3","article-title":"Comparison of steroid-pulse therapy and combined with mizoribine in IgA nephropathy: a randomized controlled trial","volume":"20","author":"Masutani","year":"2016","journal-title":"Clinical & Experimental Nephrology"},{"issue":"Abstracts","key":"10.1002\/14651858.CD003965.pub3-BIB0075|cit75","first-page":"207A","article-title":"No additional effect of oral immunosuppressive agents, mizoribine, with steroid pulse therapy in patients with IgA nephropathy: a prospective randomized controlled trial [abstract no: TH-PO441]","volume":"25","author":"Masutani","year":"2014","journal-title":"Journal of the American Society of Nephrology"},{"issue":"29","key":"10.1002\/14651858.CD003965.pub3-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"48375","DOI":"10.18632\/oncotarget.16468","article-title":"Comparison of combined leflunomide and low-dose corticosteroid therapy with full-dose corticosteroid monotherapy for progressive IgA nephropathy","volume":"8","author":"Min","year":"2017","journal-title":"Oncotarget"},{"issue":"Oct","key":"10.1002\/14651858.CD003965.pub3-BIB0077|cit77","first-page":"337A","article-title":"Omega-3 fatty acids (O3FA) for patients with IgA nephropathy (IgAN): efficacy is dose-dependent. Report from the North American (NA) IgAN trial [abstract no: SA-PO171]","volume":"15","author":"Hogg","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD003965.pub3-BIB0082|cit78","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/0272-6386(95)90445-X","article-title":"A randomized, placebo-controlled, multicenter trial evaluating alternate-day prednisone and fish oil supplements in young patients with immunoglobulin A nephropathy. Scientific Planning Committee of the IgA Nephropathy Study","volume":"26","author":"Hogg","year":"1995","journal-title":"American Journal of Kidney Diseases"},{"issue":"6","key":"10.1002\/14651858.CD003965.pub3-BIB0078|cit79","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.2215\/CJN.02300606","article-title":"Efficacy of omega-3 fatty acids in children and adults with IgA nephropathy is dosage- and size-dependent","volume":"1","author":"Hogg","year":"2006","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"3","key":"10.1002\/14651858.CD003965.pub3-BIB0079|cit80","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2215\/CJN.01020905","article-title":"Clinical trial to evaluate omega-3 fatty acids and alternate day prednisone in patients with IgA nephropathy: report from the Southwest Pediatric Nephrology Study Group","volume":"1","author":"Hogg","year":"2006","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"9","key":"10.1002\/14651858.CD003965.pub3-BIB0080|cit81","first-page":"C64","article-title":"Clinical trial of alternate-day prednisone or daily omega-3 fatty acids in patients with IgA nephropathy [abstract no: OFC10]","volume":"19","author":"Hogg","year":"2004","journal-title":"Pediatric Nephrology"},{"issue":"Nov","key":"10.1002\/14651858.CD003965.pub3-BIB0081|cit82","first-page":"751A","article-title":"Multicenter, placebo-controlled trial of alternate-day prednisone (QOD-PRED) or daily omega-3 fatty acids (OM-3 FA) in children and young adults with IgA nephropathy (IgAN). Report from the Southwest Pediatric Nephrology Study Group [abstract no: SU-PO979]","volume":"14","author":"Hogg","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD003965.pub3-BIB0083|cit83","first-page":"121","article-title":"Targeted release-budesonide (NEFECON) modifies circulating IGA-IGG immune complex levels and levels of poorly O-galactosylated IgA in IgAN [abstract]","volume":"4","author":"Bhachu","year":"2018","journal-title":"Kidney Diseases"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD003965.pub3-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"iii82","DOI":"10.1093\/ndt\/gfx129.TO013","article-title":"Proteinuria reduction in IgA nephropathy by nefecon, a targeted release formulation of budesonide - results from the NEFIGAN trial [abstract no: TO013]","volume":"32","author":"Fellstrom","year":"2017","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD003965.pub3-BIB0085|cit85","first-page":"140","article-title":"Treatment of IgA nephropathy with nefecon, a targeted-release formulation of budesonide-extended posthoc results from the NEFIGAN trial [abstract]","volume":"4","author":"Fellstrom","year":"2018","journal-title":"Kidney Diseases"},{"issue":"Abstracts","key":"10.1002\/14651858.CD003965.pub3-BIB0086|cit86","first-page":"207A","article-title":"The NEFIGAN trial: a randomized, placebo-controlled study to evaluate the efficacy and safety of NEFECON in IgA nephropathy patients at risk of developing ESRD: preliminary data from the run-in phase [abstract no: TH-PO442]","volume":"25","author":"Fellstrom","year":"2014","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstracts","key":"10.1002\/14651858.CD003965.pub3-BIB0087|cit87","first-page":"B1","article-title":"The NEFIGAN trial: NEFECON, a novel targeted release formulation of budesonide, reduces proteinuria and stabilizes eGFR in IgA nephropathy patients at risk of ESRD [abstract no: HI-OR04]","volume":"26","author":"Fellstrom","year":"2015","journal-title":"Journal of the American Society of Nephrology"},{"issue":"10084","key":"10.1002\/14651858.CD003965.pub3-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/S0140-6736(17)30550-0","article-title":"Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial","volume":"389","author":"Fellstrom","year":"2017","journal-title":"Lancet"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD003965.pub3-BIB0089|cit89","first-page":"932A","article-title":"The NEFIGAN trial: a phase 2b multicenter, randomized, placebo-controlled study to evaluate the efficacy and safety of two doses of NEFECON in primary IgA nephropathy patients at risk of developing ESRD: rationale and study design [abstract no: PUB167]","volume":"23","author":"Fellstrom","year":"2012","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD003965.pub3-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.kint.2017.05.021","article-title":"Mucosal corticosteroid therapy of IgA nephropathy","volume":"92","author":"Floege","year":"2017","journal-title":"Kidney International"},{"issue":"3","key":"10.1002\/14651858.CD003965.pub3-BIB0091|cit91","first-page":"138-9","article-title":"Targeted release-budesonide (Nefecon) modifies mucosal IgA responses and possibly gut permeability in IgA nephropathy [abstract]","volume":"4","author":"Muto","year":"2018","journal-title":"Kidney Diseases"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD003965.pub3-BIB0092|cit92","first-page":"555A","article-title":"Leflunomide plus low dose prednisone could reduce proteinuria and stabilize kidney function in progressive IgA nephropathy at 2 year follow-up study [abstract no: F-PO1967]","volume":"19","author":"Ni","year":"2008","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD003965.pub3-BIB0093|cit93","first-page":"819A","article-title":"Leflunomide plus low dose prednisone therapy in progressive IgA nephropathy at 2 year follow-up: a multi-center, perspective, randomized control study [abstract no: SU-PO1054]","volume":"18","author":"Ni","year":"2007","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstracts","key":"10.1002\/14651858.CD003965.pub3-BIB0094|cit94","first-page":"800A","article-title":"Leflunomide treatment in progressive IgA nephropathy: interim analysis from a multi-center, perspective, randomized control study [abstract no: SA-PO1080]","volume":"17","author":"Ni","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD003965.pub3-BIB0095|cit95","first-page":"523A","article-title":"Leflunomide treatment in progressive IgA nephropathy: preliminary results from a multi-center, perspective, randomized control study [abstract no: F-PO859]","volume":"16","author":"Ni","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD003965.pub3-BIB0096|cit96","first-page":"1880","article-title":"Early corticosteroid treatment (CT) in children with IgA nephropathy (IGAn): a randomized and controlled trial [abstract]","volume":"25","author":"Nuzzi","year":"2010","journal-title":"Pediatric Nephrology"},{"key":"10.1002\/14651858.CD003965.pub3-BIB0097|cit97","unstructured":"Nuzzi F D'Armiento M Malgieri G Ferretti A Marzano L Pecoraro C Early corticosteroid treatment in children with IGA nephropathy: a randomized and controlled trial [abstract no: OC005] 27th Annual Scientific Meeting; Transplantation Society of Australia & New Zealand; 2009 June 17-19; Canberra, Australia 2009 28"},{"issue":"Nov","key":"10.1002\/14651858.CD003965.pub3-BIB0098|cit98","first-page":"752A","article-title":"Renal histological picture and steroid treatment in IGA nephropathy [abstract no: SU-PO984]","volume":"14","author":"Vecchio","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3-4","key":"10.1002\/14651858.CD003965.pub3-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1081\/JDI-100104732","article-title":"Role of proteinuria reduction in the progression of IgA nephropathy","volume":"23","author":"Locatelli","year":"2001","journal-title":"Renal Failure"},{"issue":"9","key":"10.1002\/14651858.CD003965.pub3-BIB0105|cit100","first-page":"A77","article-title":"Randomized trial of steroids in IgA nephropathy with moderate proteinuria at 5 years of follow up [abstract]","volume":"12","author":"Pozzi","year":"1997","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD003965.pub3-BIB0100|cit101","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/01.ASN.0000103869.08096.4F","article-title":"Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial","volume":"15","author":"Pozzi","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9156","key":"10.1002\/14651858.CD003965.pub3-BIB0101|cit102","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0140-6736(98)03563-6","article-title":"Corticosteroids in IgA nephropathy: a randomised controlled trial","volume":"353","author":"Pozzi","year":"1999","journal-title":"Lancet"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD003965.pub3-BIB0102|cit103","first-page":"86A","article-title":"Steroid therapy in IgA nephropathy [abstract no: A0439]","volume":"10","author":"Pozzi","year":"1999","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 12","key":"10.1002\/14651858.CD003965.pub3-BIB0103|cit104","first-page":"29","article-title":"Steroid effectiveness on proteinuria reduction in IgA nephropathy [abstract no: O94]","volume":"17","author":"Pozzi","year":"2002","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD003965.pub3-BIB0104|cit105","first-page":"343","article-title":"Renal histological picture and steroid treatment in IgA nephropathy [abstract no: T193]","volume":"18","author":"Pozzi","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD003965.pub3-BIB0106|cit106","first-page":"iv327","article-title":"A multicenter randomized study to analyze the efficacy and safety of high-dose immunoglobulin therapy associated with steroids vs steroid monotherapy in patients with IgA nephropathy [abstract no: MP085]","volume":"21","author":"Segarra","year":"2006","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003965.pub3-BIB0107|cit107","first-page":"i175","article-title":"A prospective randomized study on the efficacy of corticosteroid combined with cyclophosphamide or FK506 in primary IGA nephropathy with mild or moderate renal injury [abstract no: SP308]","volume":"28","author":"Shen","year":"2013","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD003965.pub3-BIB0108|cit108","first-page":"556A","article-title":"Mannose-binding lectin gene polymorphism may predict response to leflunomide in patients with progressive IgA nephropathy [abstract no: FR-PO819]","volume":"23","author":"Shi","year":"2012","journal-title":"Journal of the American Society of Nephrology"},{"issue":"11","key":"10.1002\/14651858.CD003965.pub3-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1007\/s00467-018-4011-6","article-title":"Combination therapy with or without warfarin and dipyridamole for severe childhood IgA nephropathy: an RCT","volume":"33","author":"Shima","year":"2018","journal-title":"Pediatric Nephrology"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD003965.pub3-BIB0110|cit110","first-page":"98A","article-title":"The corticosteroid treatment of diffuse mesangial proliferative IgA nephropathy: a one-year prospective trial [abstract no: A0466]","volume":"8","author":"Shoji","year":"1997","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD003965.pub3-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0272-6386(00)70326-X","article-title":"Early treatment with corticosteroids ameliorates proteinuria, proliferative lesions, and mesangial phenotypic modulation in adult diffuse proliferative IgA nephropathy","volume":"35","author":"Shoji","year":"2000","journal-title":"American Journal of Kidney Diseases"},{"issue":"3","key":"10.1002\/14651858.CD003965.pub3-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s10157-011-0415-3","article-title":"Steroids and azathioprine in the treatment of IgA nephropathy","volume":"15","author":"Stangou","year":"2011","journal-title":"Clinical & Experimental Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD003965.pub3-BIB0113|cit113","first-page":"284","article-title":"Supportive versus immunosuppressive therapy of progressive IgA nephropathy (STOP) IgAN trial: rationale and study protocol","volume":"21","author":"Eitner","year":"2008","journal-title":"Journal of Nephrology"},{"issue":"Abstracts","key":"10.1002\/14651858.CD003965.pub3-BIB0114|cit114","first-page":"B4","article-title":"Corticosteroid monotherapy versus combined immunosuppression in IgA nephropathy: insights from the STOP-IgAN trial [abstract no: SA-PO1097]","volume":"26","author":"Floege","year":"2015","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD003965.pub3-BIB0115|cit115","unstructured":"Floege J Rauen T Eitner F Fitzner C Sommerer C Zeier M Supportive versus immunosuppressive therapy for progressive IgA nephropathy (STOP-IGAN): a randomized, controlled, open-label multicenter trial [abstract] 52nd Congress ERA-EDTA; 2015 May 28-31; London, UK 2015"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD003965.pub3-BIB0116|cit116","first-page":"14A","article-title":"The MEST kidney biopsy score predicts renal outcome in STOP-IgAN trial patients - a post-hoc study [abstract no: TH-OR057]","volume":"27","author":"Floege","year":"2016","journal-title":"Journal of the American Society of Nephrology"},{"issue":"7 Suppl","key":"10.1002\/14651858.CD003965.pub3-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"S161","DOI":"10.1016\/j.ekir.2019.05.416","article-title":"Dual blockade of the renin-angiotensin system in patients with IgA nephropathy - insights from the STOP-IGAN Trial [abstract no: SUN-021]","volume":"4","author":"Lennartz","year":"2019","journal-title":"Kidney International Reports"},{"issue":"23","key":"10.1002\/14651858.CD003965.pub3-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","article-title":"Intensive supportive care plus immunosuppression in IgA nephropathy","volume":"373","author":"Rauen","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD003965.pub3-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1681\/ASN.2017060713","article-title":"Effects of two immunosuppressive treatment protocols for IgA nephropathy","volume":"29","author":"Rauen","year":"2018","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD003965.pub3-BIB0120|cit120","first-page":"141","article-title":"Dual blockade of the renin-angiotensin system in patients with IgA nephropathy-insights from the Stop-IgAN Trial [abstract]","volume":"4","author":"Rauen","year":"2018","journal-title":"Kidney Diseases"},{"issue":"1","key":"10.1002\/14651858.CD003965.pub3-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1186\/s12882-018-1128-6","article-title":"Renal outcomes of STOP-IgAN trial patients in relation to baseline histology (MEST-C scores)","volume":"19","author":"Schimpf","year":"2018","journal-title":"BMC Nephrology"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD003965.pub3-BIB0122|cit122","first-page":"90A","article-title":"Two-year randomized controlled trial of steroid therapy for adult patients with moderately active IgA nephropathy (IgAN) [abstract no: A0463]","volume":"10","author":"Takeda","year":"1999","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD003965.pub3-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/j.1523-1755.2005.00460.x","article-title":"Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy","volume":"68","author":"Tang","year":"2005","journal-title":"Kidney International"},{"issue":"Nov","key":"10.1002\/14651858.CD003965.pub3-BIB0124|cit124","first-page":"752A","article-title":"A prospective, randomized, case-controlled study on the efficacy of mycophenolate mofetil (MMF) for IgA nephropathy (IgAN) patients with persistent proteinuria despite angiotensin blockade [abstract no: SU-PO986]","volume":"14","author":"Tang","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD003965.pub3-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/ki.2009.499","article-title":"Long-term study of mycophenolate mofetil treatment in IgA nephropathy","volume":"77","author":"Tang","year":"2010","journal-title":"Kidney International"},{"key":"10.1002\/14651858.CD003965.pub3-BIB0126|cit126","unstructured":"Lv J Zhang H Perkovic V TESTING Study Group The therapeutic evaluation of steroids in IgA nephropathy global (TESTING) study [abstract no: LB01] 53rd Congress ERA-EDTA; 2016 May 21-24; Vienna, Austria 2016"},{"issue":"5","key":"10.1002\/14651858.CD003965.pub3-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1001\/jama.2017.9362","article-title":"Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial","volume":"318","author":"Lv","year":"2017","journal-title":"JAMA"},{"issue":"3","key":"10.1002\/14651858.CD003965.pub3-BIB0128|cit128","first-page":"103","article-title":"The treatment of mesangial IgA nephropathy with cyclophosphamide, dipyridamole and warfarin: a two-year prospective trial","volume":"34","author":"Walker","year":"1990","journal-title":"Clinical Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD003965.pub3-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/S0022-3476(05)81808-6","article-title":"Double-blind, controlled trial of short-term prednisone therapy in immunoglobulin A glomerulonephritis","volume":"121","author":"Welch","year":"1992","journal-title":"Journal of Pediatrics"},{"issue":"6","key":"10.1002\/14651858.CD003965.pub3-BIB0130|cit130","first-page":"304","article-title":"Follow-up renal biopsies in IgA nephritic patients on triple therapy","volume":"28","author":"Woo","year":"1987","journal-title":"Clinical Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD003965.pub3-BIB0131|cit131","first-page":"226","article-title":"Controlled therapeutic trial of IgA nephritis with follow-up renal biopsies","volume":"17","author":"Woo","year":"1988","journal-title":"Annals of the Academy of Medicine, Singapore"},{"issue":"2","key":"10.1002\/14651858.CD003965.pub3-BIB0132|cit132","first-page":"56","article-title":"Effects of triple therapy on the progression of mesangial proliferative glomerulonephritis","volume":"27","author":"Woo","year":"1987","journal-title":"Clinical Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD003965.pub3-BIB0133|cit133","first-page":"60","article-title":"Effects of triple therapy in IgA nephritis: a follow-up study 5 years later","volume":"36","author":"Woo","year":"1991","journal-title":"Clinical Nephrology"},{"key":"10.1002\/14651858.CD003965.pub3-BIB0134|cit134","unstructured":"Woo KT Lee GS Lau YK Chiang GSC Lim CH Anti platelet therapy in IgA nephritis [abstract] 11th International Congress of Nephrology; 1990 Jul 15-20; Tokyo, Japan 1990 13"},{"issue":"Abstracts","key":"10.1002\/14651858.CD003965.pub3-BIB0135|cit135","first-page":"821A","article-title":"Efficacy and safety of telmisartan, clopidogrelin and leflunomide in patients with IgA nephropathy - a multicentre, prospective, randomized, double-blind, double-dummy controlled clinical trial [abstract no: SA-PO848]","volume":"24","author":"Chen","year":"2013","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003965.pub3-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"i175","DOI":"10.1093\/ndt\/gft113","article-title":"Efficacy and safety of telmisartan, clopidogrelin, and leflunomide in patients with IgA nephropathy - a multicentre, prospective, randomized, double-blind and-dummy controlled clinical trial [abstract no: SP307]","volume":"28","author":"Wu","year":"2013","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"16","key":"10.1002\/14651858.CD003965.pub3-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.4103\/0366-6999.187848","article-title":"Efficacy of leflunomide, telmisartan, and clopidogrel for immunoglobulin A nephropathy: a randomized controlled trial","volume":"129","author":"Wu","year":"2016","journal-title":"Chinese Medical Journal"},{"issue":"5","key":"10.1002\/14651858.CD003965.pub3-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/MAJ.0b013e318207e02d","article-title":"Efficacy and safety of mizoribine combined with losartan in the treatment of IgA nephropathy: a multicenter, randomized, controlled study","volume":"341","author":"Xie","year":"2011","journal-title":"American Journal of the Medical Sciences"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD003965.pub3-BIB0139|cit139","first-page":"259A","article-title":"Effect of steroid therapy on the progression of IgA nephropathy [abstract no: A1329]","volume":"12","author":"Yamauchi","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD003965.pub3-BIB0140|cit140","first-page":"C208","article-title":"Prospective multicenter controlled therapeutic trial in IgA nephropathy in Japanese children: a preliminary report [abstract no: S-I-2]","volume":"6","author":"Ito","year":"1992","journal-title":"Pediatric Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD003965.pub3-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.2215\/CJN.08630910","article-title":"Long-term results of a randomized controlled trial in childhood IgA nephropathy","volume":"6","author":"Kamei","year":"2011","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"5","key":"10.1002\/14651858.CD003965.pub3-BIB0143|cit142","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1093\/ndt\/14.5.1097","article-title":"Combined therapy with prednisolone, azathioprine, heparin-warfarin, and dipyridamole for paediatric patients with severe IgA nephropathy--is it relevant for adult patients?","volume":"14","author":"Yoshikawa","year":"1999","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"8","key":"10.1002\/14651858.CD003965.pub3-BIB0144|cit143","first-page":"C31","article-title":"Corticosteroids and immunosuppressive drugs [abstract]","volume":"16","author":"Yoshikawa","year":"2001","journal-title":"Pediatric Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD003965.pub3-BIB0142|cit144","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1681\/ASN.V101101","article-title":"A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. The Japanese Pediatric IgA Nephropathy Treatment Study Group","volume":"10","author":"Yoshikawa","year":"1999","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD003965.pub3-BIB0145|cit145","first-page":"1401","article-title":"A controlled trial of prednisolone (P), azathioprine (A), heparin-warfarin (H-W) and dipyridamole (D) in newly diagnosed severe childhood IgA nephropathy (IGAN) [abstract no: A0779]","volume":"7","author":"Yoshikawa","year":"1996","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD003965.pub3-BIB0149|cit146","first-page":"C57","article-title":"Treatment of IGA nephropathy in children [abstract no: FCP04]","volume":"19","author":"Yoshikawa","year":"2004","journal-title":"Pediatric Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD003965.pub3-BIB0146|cit147","doi-asserted-by":"crossref","first-page":"511","DOI":"10.2215\/CJN.01120905","article-title":"Steroid treatment for severe childhood IgA nephropathy: a randomized, controlled trial","volume":"1","author":"Yoshikawa","year":"2006","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"8","key":"10.1002\/14651858.CD003965.pub3-BIB0147|cit148","first-page":"C31","article-title":"Corticosteroids and immunosuppressive drugs [abstract]","volume":"16","author":"Yoshikawa","year":"2001","journal-title":"Pediatric Nephrology"},{"issue":"Sept","key":"10.1002\/14651858.CD003965.pub3-BIB0148|cit149","first-page":"79A","article-title":"Prednisolone therapy versus combined therapy with prednisolone, azathioprine, warfarin and dipyridamole for newly diagnosed severe childhood IgA nephropathy: a controlled trial by the Japanese Pediatric IgA Nephropathy Treatment study group [abstract no: A0430]","volume":"11","author":"Yoshikawa","year":"2000","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Oct","key":"10.1002\/14651858.CD003965.pub3-BIB0150|cit150","first-page":"337A","article-title":"Efficacy and safety of leflunomide in the treatment of IgA nephropathy: preliminary results from a randomized, corticosteroid controlled, multi-center clinical trial [abstract no: SA-PO168]","volume":"15","author":"Zhang","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstracts","key":"10.1002\/14651858.CD003965.pub3-BIB0151|cit151","first-page":"567A","article-title":"Efficacy and safety of leflunomide in the treatment of IgA nephropathy: a perspective, corticosteroid controlled, multi-center clinical trial [abstract no: F-PO1097]","volume":"17","author":"Zhang","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD003965.pub3-BIB0152|cit152","first-page":"1645","article-title":"Clinical effects of triple therapy in treatment of IgA nephropathy patients with moderate proteinuria","volume":"25","author":"Chen","year":"2009","journal-title":"Xian Dai Yi Yao Wei Sheng"},{"issue":"7","key":"10.1002\/14651858.CD003965.pub3-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1177\/0091270007301624","article-title":"Pharmacokinetics and pharmacodynamics of mycophenolic acid after enteric-coated mycophenolate versus mycophenolate mofetil in patients with progressive IgA nephritis","volume":"47","author":"Czock","year":"2007","journal-title":"Journal of Clinical Pharmacology"},{"issue":"Abstracts","key":"10.1002\/14651858.CD003965.pub3-BIB0154|cit154","first-page":"568A","article-title":"Pharmacokinetics and pharmacodynamics of mycophenolic acid after enteric-coated mycophenolate sodium and mycophenolate mofetil in patients with IgA nephritis and renal impairment [abstract no: F-PO1099]","volume":"17","author":"Keller","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD003965.pub3-BIB0155|cit155","first-page":"136","article-title":"One-year angiotensin-converting enzyme inhibition plus mycophenolate mofetil immunosuppression in the course of early IgA nephropathy: a multicenter, randomised, controlled study","volume":"18","author":"Dal Canton","year":"2005","journal-title":"Journal of Nephrology"},{"key":"10.1002\/14651858.CD003965.pub3-BIB0156|cit156","unstructured":"Harper L Randomised pilot trial of myfortic for the treatment of primary proteinuric glomerulonephritis (Short title: proteinuria in glomerulonephritis: Myfortic (GloMY)) Trial protocol - version 3.2 www.birmingham.ac.uk\/Documents\/college-mds\/trials\/bctu\/glomy\/GloMY-protocol-Version-3-2-030112.pdf"},{"issue":"1","key":"10.1002\/14651858.CD003965.pub3-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s10157-005-0396-1","article-title":"Deoxyspergualin, an immunosuppressant, in patients suffering from nephropathies with crescent formation: an open-label trial to evaluate safety and efficacy","volume":"10","author":"Imai","year":"2006","journal-title":"Clinical & Experimental Nephrology"},{"key":"10.1002\/14651858.CD003965.pub3-BIB0158|cit158","first-page":"154","article-title":"Effects of a combined regime of Tripterygium wilfordii glycosides and benazepril in treatment of IgA nephropathy","volume":"10","author":"Shen","year":"2009","journal-title":"Zhong Guo Zhong Xi Yi jie He Shen Bing Za Zhi"},{"issue":"2","key":"10.1002\/14651858.CD003965.pub3-BIB0159|cit159","first-page":"229","article-title":"Difficult nephropathies: a multicenter randomized trial on the treatment [abstract]","volume":"12","author":"Sulimani","year":"2001","journal-title":"Saudi Journal of Kidney Diseases & Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD003965.pub3-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/PL00005832","article-title":"Short-term effect of vitamin K administration on prednisolone-induced loss of bone mineral density in patients with chronic glomerulonephritis","volume":"66","author":"Yonemura","year":"2000","journal-title":"Calcified Tissue International"},{"key":"10.1002\/14651858.CD003965.pub3-BIB0161|cit161","unstructured":"Li LS Mycophenolate mofetil versus intravenous cyclophosphamide pulses in the treatment of crescentic IgA nephropathy www.clinicaltrials.gov\/ct2\/show\/NCT00301600"},{"key":"10.1002\/14651858.CD003965.pub3-BIB0162|cit162","unstructured":"Deng Y A controlled study of steroids therapy for patients of IgA nephropathy with active pathological changes www.ClinicalTrials.gov\/show\/NCT02160132 2014"},{"key":"10.1002\/14651858.CD003965.pub3-BIB0163|cit163","unstructured":"Chancharoenthana W Rituximab in recurrent IgA nephropathy www.ClinicalTrials.gov\/show\/NCT02571842"},{"key":"10.1002\/14651858.CD003965.pub3-BIB0164|cit164","unstructured":"Kim C Lee D Lee S Choi B Han S Lee S Efficacy and safety of a combination of mycophenolate mofetil and corticosteroid in advanced IgA nephropathy (AIGA) www.clinicalTrials.gov\/show\/NCT02981212"},{"key":"10.1002\/14651858.CD003965.pub3-BIB0165|cit165","unstructured":"NCT03608033 Study of the safety and efficacy of OMS721 in patients with immunoglobulin A (IgA) nephropathy www.clinicaltrials.gov\/show\/nct03608033"},{"key":"10.1002\/14651858.CD003965.pub3-BIB0166|cit166","unstructured":"Li Y Fu RG Prospective study of the efficacy and safety of improved Italy scheme therapy for IgA nephropathy www.chictr.org.cn\/showprojen.aspx?proj=24628"},{"key":"10.1002\/14651858.CD003965.pub3-BIB0167|cit167","unstructured":"Hou F The effects of mycophenolate mofetil (MMF) on renal outcomes in advanced immunoglobulin A (IgA) nephropathy patients www.ClinicalTrials.gov\/show\/NCT01854814"},{"key":"10.1002\/14651858.CD003965.pub3-BIB0168|cit168","unstructured":"Yu X Yang Q Mycophenolate mofetil (MMF) in patients with IgA nephropathy (IgAN) www.clinicaltrials.gov\/ct2\/show\/NCT00657059"},{"key":"10.1002\/14651858.CD003965.pub3-BIB0169|cit169","unstructured":"NCT02808429 Efficacy and safety of atacicept in IgA nephropathy www.ClinicalTrials.gov\/show\/NCT02808429"},{"key":"10.1002\/14651858.CD003965.pub3-BIB0170|cit170","unstructured":"Han SH Effect of immunosuppression in IgA nephropathy www.clinicaltrials.gov\/show\/nct03468972"},{"key":"10.1002\/14651858.CD003965.pub3-BIB0171|cit171","unstructured":"NCT03643965 Efficacy and safety of Nefecon in patients with primary IgA (immunoglobulin A) nephropathy (Nefigard) www.clinicaltrials.gov\/ct2\/show\/NCT03643965"},{"key":"10.1002\/14651858.CD003965.pub3-BIB0172|cit172","unstructured":"Berthoux F Prevention in recipients with primary IgA Nephropathy of recurrence after kidney transplantation: ATG-F versus basiliximab as induction immunosuppressive treatment (PIRAT) www.ClinicalTrials.gov\/show\/NCT02523768"},{"issue":"7 Suppl","key":"10.1002\/14651858.CD003965.pub3-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"S168","DOI":"10.1016\/j.ekir.2019.05.431","article-title":"Spleen tyrosine kinase (SYK) inhibition in IgA nephropathy: a global, phase ii, randomised placebo-controlled trial of fostamatinib [abstract no: SUN-036]","volume":"4","author":"Tam","year":"2019","journal-title":"Kidney International Reports"},{"key":"10.1002\/14651858.CD003965.pub3-BIB0174|cit174","unstructured":"Joly D Alarmartine E Treatment of IgA nephropathy according to renal lesions (TIGER) www.ClinicalTrials.gov\/show\/NCT03188887"},{"key":"10.1002\/14651858.CD003965.pub3-BIB0175|cit175","unstructured":"Shi W Extended follow-up of treatment of prednisone plus cyclophosphamide in patients with advanced-stage IgA nephropathy (e-TOPplus) www.ClinicalTrials.gov\/show\/NCT03218852"},{"key":"10.1002\/14651858.CD003965.pub3-BIB0176|cit176","unstructured":"Shi W Treatment of prednisone plus cyclophosphamide in patients with advanced-stage IgA nephropathy (TOPplus-IgAN) www.ClinicalTrials.gov\/show\/NCT01758120"},{"key":"10.1002\/14651858.CD003965.pub3-BIB0177|cit177","unstructured":"Suzuki H The steroid internal use method for patients with IgA nephropathy upload.umin.ac.jp\/cgi-open-bin\/ctr_e\/ctr_view.cgi?recptno=R000036551"},{"issue":"7","key":"10.1002\/14651858.CD003965.pub3-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1001\/jamainternmed.2019.0600","article-title":"Evaluating a new international risk-prediction tool in IgA nephropathy","volume":"179","author":"Barbour","year":"2019","journal-title":"JAMA Internal Medicine"},{"issue":"9","key":"10.1002\/14651858.CD003965.pub3-BIB0179|cit179","first-page":"694","article-title":"Intercapillary deposits of IgA-IgG","volume":"74","author":"Berger","year":"1968","journal-title":"Journal d Urologie et de Nephrologie"},{"issue":"5","key":"10.1002\/14651858.CD003965.pub3-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/ki.2009.243","article-title":"The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification","volume":"76","author":"Cattran","year":"2009","journal-title":"Kidney International"},{"issue":"2","key":"10.1002\/14651858.CD003965.pub3-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/nep.12359","article-title":"Valsartan combined with clopidogrel and\/or leflunomide for the treatment of progressive immunoglobulin A nephropathy","volume":"20","author":"Cheng","year":"2015","journal-title":"Nephrology"},{"key":"10.1002\/14651858.CD003965.pub3-BIB0182|cit182","first-page":"S13-21","article-title":"Treatment of IgA nephropathy: recent advances and prospects","volume":"14 Suppl 1","author":"Coppo","year":"2018","journal-title":"Nephrologie et Therapeutique"},{"issue":"245","key":"10.1002\/14651858.CD003965.pub3-BIB0183|cit183","first-page":"709","article-title":"The commonest glomerulonephritis in the world: IgA nephropathy","volume":"64","author":"D'Amico","year":"1987","journal-title":"Quarterly Journal of Medicine"},{"issue":"7109","key":"10.1002\/14651858.CD003965.pub3-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"7","key":"10.1002\/14651858.CD003965.pub3-BIB0185|cit185","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1681\/ASN.2016091043","article-title":"Galactosylation of IgA1 Is Associated with Common Variation in C1GALT1","volume":"28","author":"Gale","year":"2017","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD003965.pub3-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S0272-6386(88)80025-8","article-title":"Prognostic pathologic markers in IgA nephropathy","volume":"12","author":"Gallo","year":"1988","journal-title":"American Journal of Kidney Diseases"},{"issue":"7650","key":"10.1002\/14651858.CD003965.pub3-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD003965.pub3-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD003965.pub3-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1681\/ASN.2016040433","article-title":"A multicenter study of the predictive value of crescents in IgA nephropathy.[Erratum in: J Am Soc Nephrol. 2017 May;28(5):1665; PMID: 28455358]","volume":"28","author":"Haas","year":"2017","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD003965.pub3-BIB0190|cit190","first-page":"1570-75","article-title":"Spontaneous remission of nephrotic syndrome in patients with IgA nephropathy","volume":"26","author":"Han","year":"2010","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"7414","key":"10.1002\/14651858.CD003965.pub3-BIB0191|cit191","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD003965.pub3-BIB0192|cit192","unstructured":"Higgins JP Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"3","key":"10.1002\/14651858.CD003965.pub3-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1046\/j.1523-1755.2001.0590031077.x","article-title":"Mass spectrometry proves under-O-glycosylation of glomerular IgA1 in IgA nephropathy","volume":"59","author":"Hiki","year":"2001","journal-title":"Kidney International"},{"issue":"5","key":"10.1002\/14651858.CD003965.pub3-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"e194772","DOI":"10.1001\/jamanetworkopen.2019.4772","article-title":"Association between tonsillectomy and outcomes in patients with immunoglobulin A nephropathy","volume":"2","author":"Hirano","year":"2019","journal-title":"JAMA Network Open"},{"issue":"5","key":"10.1002\/14651858.CD003965.pub3-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1053\/j.ajkd.2015.06.013","article-title":"Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy","volume":"66","author":"Hogg","year":"2015","journal-title":"American Journal of Kidney Diseases"},{"issue":"4","key":"10.1002\/14651858.CD003965.pub3-BIB0196|cit196","doi-asserted-by":"crossref","first-page":"736-43","DOI":"10.1053\/ajkd.2001.27690","article-title":"Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy","volume":"38","author":"Hotta","year":"2001","journal-title":"American Journal of Kidney Diseases"},{"issue":"11","key":"10.1002\/14651858.CD003965.pub3-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"e0187607","DOI":"10.1371\/journal.pone.0187607","article-title":"Seasonal proteinuria changes in IgA nephropathy patients after proteinuria remission","volume":"12","author":"Inagaki","year":"2017","journal-title":"PLoS ONE [Electronic Resource]"},{"issue":"2","key":"10.1002\/14651858.CD003965.pub3-BIB0198|cit198","first-page":"139","article-title":"KDIGO clinical practice guideline for glomerulonephritis","volume":"2","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group","year":"2012","journal-title":"Kidney International - Supplement"},{"issue":"4","key":"10.1002\/14651858.CD003965.pub3-BIB0199|cit199","doi-asserted-by":"crossref","first-page":"118","DOI":"10.12771\/emj.2016.39.4.118","article-title":"A patient with IgA nephropathy: 5 years after complete remission of minimal change nephrotic syndrome","volume":"39","author":"Kim","year":"2016","journal-title":"EWHA Medical Journal"},{"issue":"6","key":"10.1002\/14651858.CD003965.pub3-BIB0200|cit200","doi-asserted-by":"crossref","first-page":"e1002765","DOI":"10.1371\/journal.pgen.1002765","article-title":"Geographic differences in genetic susceptibility to IgA nephropathy: GWAS replication study and geospatial risk analysis","volume":"8","author":"Kiryluk","year":"2012","journal-title":"PLoS Genetics"},{"issue":"8","key":"10.1002\/14651858.CD003965.pub3-BIB0201|cit201","first-page":"2055","article-title":"Drug-induced reduction in albuminuria is associated with subsequent renoprotection: a meta-analysis","volume":"26","author":"Lambers Heerspink","year":"2015","journal-title":"American Journal of Kidney Diseases"},{"key":"10.1002\/14651858.CD003965.pub3-BIB0202|cit202","first-page":"6289478","article-title":"Potential association of body constitution with the prognosis of IgA nephropathy: a long-time follow-up of 203 cases in China","author":"Liu","year":"2019","journal-title":"Evidence-Based Complementary & Alternative Medicine: eCAM"},{"issue":"7","key":"10.1002\/14651858.CD003965.pub3-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1681\/ASN.2014101000","article-title":"Current understanding of the role of complement in IgA nephropathy","volume":"26","author":"Maillard","year":"2015","journal-title":"Journal of the American Society of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD003965.pub3-BIB0204|cit204","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1053\/j.ajkd.2007.03.013","article-title":"A novel simpler histological classification for renal survival in IgA nephropathy: a retrospective study","volume":"49","author":"Manno","year":"2007","journal-title":"American Journal of Kidney Diseases"},{"key":"10.1002\/14651858.CD003965.pub3-BIB0205|cit205","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000422410","article-title":"Defective galactosylation and clearance of IgA1 molecules as a possible etiopathogenic factor in IgA nephropathy","volume":"104","author":"Mestecky","year":"1993","journal-title":"Contributions to Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD003965.pub3-BIB0206|cit206","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1007\/s10157-019-01735-4","article-title":"Clinical and histological features and therapeutic strategies for IgA nephropathy","volume":"23","author":"Moriyama","year":"2019","journal-title":"Clinical & Experimental Nephrology"},{"key":"10.1002\/14651858.CD003965.pub3-BIB0207|cit207","unstructured":"A study of cemdisiran in adults with immunoglobulin A nephropathy (IgAN) www.clinicaltrials.gov\/ct2\/show\/NCT03841448"},{"issue":"3","key":"10.1002\/14651858.CD003965.pub3-BIB0208|cit208","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/ki.1988.57","article-title":"Proteinuria in IgA nephropathy","volume":"33","author":"Neelakantappa","year":"1988","journal-title":"Kidney International"},{"key":"10.1002\/14651858.CD003965.pub3-BIB0209|cit209","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1046\/j.1523-1755.1999.07008.x","article-title":"Management of IgA nephropathy: evidence-based recommendations","volume":"70","author":"Nolin","year":"1999","journal-title":"Kidney International - Supplement"},{"issue":"8","key":"10.1002\/14651858.CD003965.pub3-BIB0210|cit210","doi-asserted-by":"crossref","first-page":"2583-9","DOI":"10.1093\/ndt\/gfq107","article-title":"Influence of tonsillectomy on the progression of mesangioproliferative glomerulonephritis","volume":"25","author":"Piccoli","year":"2010","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"10","key":"10.1002\/14651858.CD003965.pub3-BIB0211|cit211","doi-asserted-by":"crossref","first-page":"1783-90","DOI":"10.1681\/ASN.2010010117","article-title":"Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy","volume":"21","author":"Pozzi","year":"2010","journal-title":"Journal of the American Society of Nephrology"},{"issue":"12","key":"10.1002\/14651858.CD003965.pub3-BIB0212|cit212","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1681\/ASN.2007050526","article-title":"Remission of proteinuria improves prognosis in IgA nephropathy","volume":"18","author":"Reich","year":"2007","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD003965.pub3-BIB0213|cit213","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003962.pub2","article-title":"Non-immunosuppressive treatment for IgA nephropathy","author":"Reid","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD003965.pub3-BIB0214|cit214","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/ki.1991.313","article-title":"Deterioration of GFR in IgA nephropathy as measured by 51Cr-EDTA clearance","volume":"40","author":"Rekola","year":"1991","journal-title":"Kidney International"},{"issue":"3","key":"10.1002\/14651858.CD003965.pub3-BIB0215|cit215","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1159\/000188480","article-title":"Immunomodulation with low-dose immunoglobulins for moderate IgA nephropathy and Henoch-Schonlein purpura. Preliminary results of a prospective uncontrolled trial","volume":"69","author":"Rostoker","year":"1995","journal-title":"Nephron"},{"issue":"6","key":"10.1002\/14651858.CD003965.pub3-BIB0216|cit216","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0002-9343(01)00684-2","article-title":"Immunoglobulin A nephropathy with mild renal lesions: a call in the forest for physicians and nephrologists","volume":"110","author":"Schena","year":"2001","journal-title":"American Journal of Medicine"},{"key":"10.1002\/14651858.CD003965.pub3-BIB0217|cit217","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1142\/9789812835871_0002","article-title":"Chapter 2: Epidemiology and ancestral difference","volume-title":"Recent advances in IgA nephropathy","author":"Schena","year":"2009"},{"key":"10.1002\/14651858.CD003965.pub3-BIB0218|cit218","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JP Vist GE Glasziou P Guyatt GH Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD003965.pub3-BIB0219|cit219","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JP Deeks JJ Glasziou P Guyatt GH Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"1","key":"10.1002\/14651858.CD003965.pub3-BIB0220|cit220","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12882-017-0467-z","article-title":"Efficacy and safety of calcineurin inhibitor treatment for IgA nephropathy: a meta-analysis","volume":"18","author":"Song","year":"2017","journal-title":"BMC Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD003965.pub3-BIB0221|cit221","doi-asserted-by":"crossref","first-page":"2248-58","DOI":"10.1681\/ASN.2014070697","article-title":"Corticosteroids in IgA nephropathy: a retrospective analysis from the VALIGA study","volume":"26","author":"Tesar","year":"2015","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD003965.pub3-BIB0222|cit222","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.kint.2017.02.003","article-title":"Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group","volume":"91","author":"Trimarchi","year":"2017","journal-title":"Kidney International"},{"issue":"2","key":"10.1002\/14651858.CD003965.pub3-BIB0223|cit223","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s004670000517","article-title":"Evidence-based assessment of treatment options for children with IgA nephropathies","volume":"16","author":"Wyatt","year":"2001","journal-title":"Pediatric Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD003965.pub3-BIB0224|cit224","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.ekir.2018.03.006","article-title":"Comparative efficacy and safety of therapies in IgA nephropathy: a network meta-analysis of randomized controlled trials","volume":"3","author":"Yang","year":"2018","journal-title":"KI Reports"},{"issue":"3","key":"10.1002\/14651858.CD003965.pub3-BIB0225|cit225","first-page":"1882","article-title":"Efficacy and safety of mycophenolate mofetil for IgA nephropathy: An updated meta-analysis of randomized controlled trials","volume":"16","author":"Zheng","year":"2018","journal-title":"Experimental & Therapeutic Medicine"},{"issue":"1","key":"10.1002\/14651858.CD003965.pub3-BIB0226|cit226","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003965","article-title":"Immunosuppressive and cytotoxic agents for treating IgA nephropathy","author":"Samuels","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD003965.pub3-BIB0227|cit227","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003965","article-title":"Immunosuppressive agents for treating IgA nephropathy","author":"Samuels","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD003965.pub3-BIB0228|cit228","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1440-1797.2004.00255.x","article-title":"Immunosuppressive treatments for immunoglobulin A nephropathy: a meta-analysis of randomized controlled trials","volume":"9","author":"Samuels","year":"2004","journal-title":"Nephrology"},{"issue":"8","key":"10.1002\/14651858.CD003965.pub3-BIB0229|cit229","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003965.pub2","article-title":"Immunosuppressive agents for treating IgA nephropathy","author":"Vecchio","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T14:07:11Z","timestamp":1666102031000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD003965.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Kidney and Transplant Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,3,12]]},"references-count":229,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd003965.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,12]]}}}